These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 22502948)

  • 1. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.
    Chen AP; Setser A; Anadkat MJ; Cotliar J; Olsen EA; Garden BC; Lacouture ME
    J Am Acad Dermatol; 2012 Nov; 67(5):1025-39. PubMed ID: 22502948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
    Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
    Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug toxicodermias].
    Korolev IuF
    Vestn Dermatol Venerol; 1980 Oct; (10):26-32. PubMed ID: 6449790
    [No Abstract]   [Full Text] [Related]  

  • 4. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
    Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
    Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management.
    Hu JC; Sadeghi P; Pinter-Brown LC; Yashar S; Chiu MW
    J Am Acad Dermatol; 2007 Feb; 56(2):317-26. PubMed ID: 17141360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lapatinib side-effect management.
    Frankel C; Palmieri FM
    Clin J Oncol Nurs; 2010 Apr; 14(2):223-33. PubMed ID: 20350896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathology and management of dermatologic toxicities associated with anti-EGFR therapy.
    Fox LP
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):26-34. PubMed ID: 16736980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serious and life-threatening drug eruptions.
    Manders SM
    Am Fam Physician; 1995 Jun; 51(8):1865-72. PubMed ID: 7762478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous reactions to drugs with special reference to severe bullous mucocutaneous eruptions and sulphonamides.
    Kauppinen K
    Acta Derm Venereol Suppl (Stockh); 1972; 68():1-89. PubMed ID: 4403517
    [No Abstract]   [Full Text] [Related]  

  • 10. Cutaneous side-effects of EGFR inhibitors and their management.
    Ehmann LM; Ruzicka T; Wollenberg A
    Skin Therapy Lett; 2011 Jan; 16(1):1-3. PubMed ID: 21293833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 12. Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.
    Dreyfus B; Kawabata H; Gomez A
    Cancer Epidemiol; 2013 Apr; 37(2):191-6. PubMed ID: 23246035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse cutaneous drug reactions].
    Rupec RA; Boneberger S; Ruzicka T
    Dtsch Med Wochenschr; 2007 Dec; 132(50):2685-94. PubMed ID: 18058660
    [No Abstract]   [Full Text] [Related]  

  • 14. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
    Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
    J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
    Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
    Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Do late drug-induced erythematous reactions exist?].
    Rodolakis P
    Ann Dermatol Venereol; 1999 Feb; 126(2):187-90. PubMed ID: 10352842
    [No Abstract]   [Full Text] [Related]  

  • 17. Skin Manifestations of Targeted Antineoplastic Therapy.
    Sanmartín O
    Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition.
    Wollenberg A; Moosmann N; Klein E; Katzer K
    Exp Dermatol; 2008 Sep; 17(9):790-2. PubMed ID: 18503553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
    Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
    Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
    Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
    Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.